A U.S. House Select Committee on China investigation is examining clinical trials conducted at Chinese military hospitals and in Xinjiang involving U.S. companies. The probe adds compliance and operational risk for sponsors that rely on China-based clinical evidence for global registrational strategies. Industry sources in the coverage said the scrutiny could create “huge distraction and expense,” reflecting the administrative overhead needed for site assessment, documentation, and potential trial replanning. For biotech executives, the development increases uncertainty around evidence acceptance timelines and may drive additional legal and regulatory diligence for cross-border trial partnerships.